Delving into the Latest Updates on LM-102 with Synapse

This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2). It is being tested in advanced solid tumors including gastric cancer/gastroesophageal junction adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, esophageal adenocarcinoma and ovarian mucous carcinoma.

Start Date06 Oct 2021

Sponsor / Collaborator

LaNova Medicines Ltd.

[+4]

NCT04735796 / TerminatedPhase 1

A Phase I, First-in-Human, Open-Label, Dose Escalation Study of LM-102 Injection in Subjects With CLDN18.2-Positive Advanced Solid Tumors

This is a phase Ⅰ, first-in-human, open-label, dose escalation study to evaluate the safety and tolerability, PK, immunogenicity and preliminary anti-tumor activity of LM-102 injection in subjects with CLDN18.2-positive advanced solid tumors.

Start Date27 May 2021

Sponsor / Collaborator

LaNova Medicines (Zhejiang) Co., Ltd.

100 Clinical Results associated with LM-102

Login to view more data

100 Translational Medicine associated with LM-102

Login to view more data

100 Patents (Medical) associated with LM-102

Login to view more data

2

Literatures (Medical) associated with LM-102

01 May 2020·Gene

Identifying heat shock response systems from the genomic assembly of Ureibacillus thermophilus LM102 using protein-protein interaction networks

Article

Author: Sunny, Jithin S ; Saleena, Lilly M ; Natarajan, Anuradha ; Mukund, Nisha

Ureibacillus thermophilus strain LM102 is a facultative thermophile with growth in range 37 °C-60 °C. Upon identification using the 16S rRNA marker, it showed highest similarity of 99.8% with U. thermophilus strain HC148. A phylogenetic analysis revealed U. suwonensis strain 6 T19 to be the closest species to strain LM102. Our aim was to determine the unique thermotolerant properties of LM102 by identifying thermostablity of its proteins and the interactions existing in its heat shock response systems (HSRS). The strain was sequenced, assembled and the draft genome (3,017,325 bp) was analyzed. Post-annotation, we randomly selected a set of hundred proteins and computed the percentage distribution of 12 amino acids which have been substantially studied for their role in thermostability. The protein homologues were searched and the residues of LM102 were compared with Bacillus subtilis and Thermus thermophilus, a mesophile and hyperthermophile respectively. Within the 95% confidence limit, a Z-score of -0.61 was observed between LM102 and B. subtilis. However, a significantly lower value of -8.84 was observed for the pair LM102 and T. thermophilus. The amino acid distribution did not appear to influence the protein thermostability. Further, we investigated the role of Protein-Protein interactions by building networks for heat shock responses, namely DNA repair, transcriptional regulation, and activation of heat shock proteins. Interaction data retrieved from the STRING database for more than 50 species were used to build these networks. Highly clustered MCODE results notably revealed RNA 3'-5' exonuclease, CshA and HemW previously unreported, in association with other proteins. Additionally, these and other proteins estimated from the HSRS networks were found in both mesophiles and thermophiles, suggesting a crucial role of gene regulatory networks in the cellular viability of LM102 at high temperatures.

28 Oct 2018·Journal of Microbiology and BiotechnologyQ4 · ENGINEERING & TECHNOLOGY

Development of a Highly Active Fluorescence-Based Detector for Yeast G Protein-Coupled Receptor Ste2p

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Jin, Dong Hoon ; Hong, Nam Joo ; Hong, Eun Young ; Ahn, Hee Jun ; Hong, Jin Woo ; Khang, Yong Ho ; Baek, Jee Su

Twenty analogs of [Orn⁶,D-Ala⁹]α-factor were synthesized and assayed for their biological activities: seven analogs of [Orn⁶,X⁹]α-factor, seven analogs of [X⁶,D-Ala⁹]α-factor, five analogs of [X⁵,X⁶,D-Ala⁹]α-factor, and native α-factor (X = amino acids). Their biological activities (halo, gene induction, and affinity) were measured using S. cerevisiae Y7925 and LM102 and compared with those of native α-factor (100%). G protein-coupled receptor was expressed in strain LM102 containing pESC-LEU-STE2 vector. [Dap⁶,D-Ala⁹]α-factor with weak halo activity (10%) showed the highest receptor affinity (＞ 230%) and the highest gene induction activity (167%). [Arg⁶,D-Ala⁹]α-factor showed the highest halo activity (2,000%). The number of active binding sites per cell (about 20,000 for strain LM102) was determined using a newly-designed fluorescence-based detector, [Arg⁶,D-Ala⁹]α-factor-Edan, with high sensitivity (12,500-fold higher than the absorption-based detector [Orn⁶]α-factor-[Cys]₃).

100 Deals associated with LM-102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bile Duct Neoplasms	IND Approval	CN	Shanghai LaNova Medicines Research and Development Co Ltd	27 Oct 2022
Pancreatic Cancer	IND Approval	CN	Shanghai LaNova Medicines Research and Development Co Ltd	27 Oct 2022
Stomach Cancer	IND Approval	CN	Shanghai LaNova Medicines Research and Development Co Ltd	27 Oct 2022
Advanced Malignant Solid Neoplasm	Preclinical	CN	LaNova Medicines Ltd.	06 Oct 2021
CLDN18.2 positive Solid Tumors	Preclinical	CN	LaNova Medicines Ltd.	06 Oct 2021